Bioimpacts最新文献

{"title":"Marine fungal metabolites as antiviral agents: Computer-aided drug screening for selective inhibition of African swine fever virus dUTPase.","authors":"Mark Andrian B Macalalad, Fredmoore L Orosco","doi":"10.34172/bi.30815","DOIUrl":"10.34172/bi.30815","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>African swine fever (ASF) continues to be a significant threat to the global livestock industry due to its severe impact on pig populations. Currently, there are no approved therapeutic agents for the virus, and biosecurity measures such as culling have led to substantial economic losses. In light of its effects on food security and the economy, our study aims to identify potential antiviral compounds from marine fungal metabolites that target the dUTPase enzyme of the African swine fever virus (ASFV).</p><p><strong>Methods: </strong>We screened 4,683 marine fungal metabolites using a series of virtual screening techniques. These included ADMET profiling to assess drug-likeness, consensus molecular docking to predict preferred docking poses and rank the docking scores, 300 ns molecular dynamics (MD) simulations to determine stability, principal component analysis (PCA) to verify simulation convergence, and MMPB(GB)SA analysis to estimate binding affinity.</p><p><strong>Results: </strong>Of the 4,683 compounds, 328 passed our ADMET filter, and the 10 highest-scoring ligands from molecular docking were evaluated for stability and binding affinity against both swine and ASFV dUTPase. Among the candidates, tricycloalternarene C (M1421), derived from <i>Alternaria</i> sp., emerged as a promising candidate. It exhibited excellent drug-likeness, stability, and binding affinity comparable to the three control compounds, while showing less affinity towards the swine dUTPase.</p><p><strong>Conclusion: </strong>Tricycloalternarene C holds potential as a selective inhibitor of ASFV dUTPase. We recommend further experimental validation to confirm its efficacy as an antiviral agent against African swine fever.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30815"},"PeriodicalIF":2.2,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12579737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145439782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR-T cell therapy as an approach for pediatric hematological malignancies in regenerative therapy: Current status and clinical outcomes.","authors":"Xiaoman Guo, Xueyin Jiang, Juan Zhang","doi":"10.34172/bi.31459","DOIUrl":"10.34172/bi.31459","url":null,"abstract":"<p><p>Radiation therapy, chemotherapy, and surgery have been the standard cancer treatment approaches for many years. Even with these treatments, the majority of tumors still have a dismal prognosis. With complete remission rates ranging from 65% to 90% in the crucial CD19-CART trials, chimeric antigen receptor T-cell (CART) therapy has revolutionized the treatment paradigm for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Hematological tumors have responded well to CART. The first CART was authorized by the FDA in 2017 to treat B-ALL. The FDA authorized CART to treat B-cell lymphoma in October of that year. In recent years, research has focused on CART to increase and improve the therapeutic effect. New toxicity profiles and treatment constraints have also surfaced with this new medicine, calling for cooperative group trials, new management strategies, and toxicity consensus grading systems. The introduction of CART treatment for pediatric B-cell ALL will be the main topic of this article, along with previous and ongoing trials. We will also talk about CART therapy trials for various pediatric cancers. Safe procedures and close observation are essential since CART treatment has the potential to cause serious toxicities.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"31459"},"PeriodicalIF":2.2,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12579741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145439848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advancement in polymeric nanoparticles for oral chemotherapy: Transforming cancer treatment.","authors":"Karthik Mangu, Ruhan Gudeli, Md Rizwanullah","doi":"10.34172/bi.31117","DOIUrl":"10.34172/bi.31117","url":null,"abstract":"<p><p>Oral chemotherapy offers an attractive alternative to conventional intravenous administration by providing high patient compliance and improved treatment adherence. However, several challenges, like poor drug solubility, enzymatic degradation, and extensive first-pass metabolism, have significantly limited the oral bioavailability of chemotherapeutic agents. Recently, polymeric nanoparticles (PNPs) have become an alternative strategy to overcome these challenges and revolutionize the oral chemotherapeutic approach. PNPs offer unique advantages, including drug protection from harsh gastrointestinal conditions, controlled release profiles, and enhanced mucosal adhesion, which collectively improve drug absorption and therapeutic efficacy. Additionally, surface-modified PNPs can bypass efflux transporters such as P-glycoprotein and promote receptor-mediated endocytosis to achieve targeted delivery and minimize systemic toxicity. While these advancements highlight the transformative potential of PNPs in oral chemotherapy, potential clinical challenges such as scalability, reproducibility, and regulatory hurdles must be addressed to enable successful clinical translation. The present review comprehensively explores the role of PNPs in enhancing the oral delivery of cancer therapeutics, emphasizing strategies to improve drug stability, prolong gastrointestinal retention, and facilitate efficient cellular uptake. The advancements discussed herein underscore the transformative potential of PNPs as a pivotal approach for improving oral chemotherapy outcomes and expanding therapeutic possibilities in cancer management.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"31117"},"PeriodicalIF":2.2,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12579739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145439765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ambivalent roles of miRNAs in cancer development via modulating tumor-associated innate immune cells.","authors":"Bahar Naseri, Amirhossein Mardi, Najibeh Shekari, Neda Shajari, Samin Abdolzadeh, Hossein Khorramdelazad, Amirhossein Hatami-Sadr, Milad Taghizadeh Anvar, Mohammad Reza Javan, Amirhossein Heibatollahi, Javad Masoumi, Farid Ghorbaninezhad, Behzad Baradaran","doi":"10.34172/bi.31430","DOIUrl":"10.34172/bi.31430","url":null,"abstract":"<p><p>The tumor microenvironment (TME), comprising malignant and non-transformed cells like immune cells, endothelial cells, and cancer-associated fibroblasts, significantly affects tumor growth and progression. Tumor cells manipulate the TME by releasing chemokines and inhibitory cytokines, reprogramming surrounding cells to support their survival and evade immune detection. Innate immune cells within the TME play dual roles, either promoting or inhibiting tumor progression, impacting immunotherapy outcomes. Recent studies highlight the influence of innate immune cells in shaping the TME and the pivotal role of tumor-derived microRNAs (miRNAs) in modulating these cells. miRNAs regulate gene expression and enhance tumor immune evasion, angiogenesis, drug resistance, and invasion. Their tumor-specific expression patterns suggest potential as biomarkers and therapeutic targets. This study focuses on how miRNAs affect innate immune cells like macrophages, dendritic cells, myeloid-derived suppressor cells, and natural killer cells, contributing to immunosuppressive or immunogenic environments. Understanding miRNA-mediated interactions between cancer and immune cells opens new possibilities for improving targeted immunotherapy and advancing cancer treatments.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"31430"},"PeriodicalIF":2.2,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12705287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145775772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of non-coding RNA through nanomedicine: the novel therapeutic and diagnostic approaches.","authors":"Kamyar Khoshnevisan, Mohammad J Eslamizade, Forough Shams","doi":"10.34172/bi.31239","DOIUrl":"10.34172/bi.31239","url":null,"abstract":"<p><p>In today's rapidly advancing field of medical research, non-coding RNA (ncRNA) and nanomedicine have emerged as promising areas of study for therapeutic and diagnostic approaches. ncRNAs, previously considered \"junk DNA\" and hence insignificant, are now being documented for their remarkably extraordinary regulatory roles in gene expression and various cellular processes. These molecules acquire various forms, comprising microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and small interfering RNAs (siRNAs), each with its distinct functions. The enormous benefits of ncRNA therapies include ease of sequence design and creation, functional flexibility, charge and protection, and the opportunity for patient-specific management. Nanomedicine, on the other hand, combines nanotechnology and medicine through developing innovative solutions for disease treatment and diagnosis. This article provides an overview of the technical aspects and potential of commercializing the design and targeting of ncRNAs using nanocarriers and nano-delivery systems for miRNA delivery. Furthermore, the impact of nanomedicine on the healthcare industry, as well as its therapeutic and diagnostic applications, has been investigated. Overall, this study will provide insight into novel systems for the treatment and diagnosis of ncRNA.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"31239"},"PeriodicalIF":2.2,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12579740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145439819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Designing of multi-epitope vaccine against Varicella zoster virus (VZV) using immunoinformatics and structural analysis: In silico study.","authors":"Mohamed J Saadh, Mareb Hamed Ahmed, Rafid Jihad Albadr, Gaurav Sanghvi, R Roopashree, Aditya Kashyap, A Sabarivani, Zafar Aminov, Waam Mohammed Taher, Mariem Alwan, Mahmod Jasem Jawad, Ali M Ali Al-Nuaimi","doi":"10.34172/bi.30994","DOIUrl":"10.34172/bi.30994","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>The Varicella-zoster virus (VZV) causes varicella (chickenpox) and herpes zoster (shingles), posing significant global health challenges. Despite existing vaccines, gaps in coverage and efficacy persist, necessitating novel vaccine designs. This study aimed to develop a multi-epitope vaccine targeting VZV using immunoinformatics and structural bioinformatics approaches.</p><p><strong>Methods: </strong>MHC-I and MHC-II binding epitopes from VZV proteins (glycoprotein E, glycoprotein B, tegument protein IE63) were predicted using IEDB tools, prioritizing conserved epitopes with high binding affinity. A chimeric construct was engineered with 18 epitopes, adjuvants (β-defensin 3), and cell-penetrating peptides (HIV TAT), linked with GPGPG/AAY spacers. Antigenicity (VaxiJen), allergenicity (AlgPred), physicochemical properties (ProtParam), and solubility (SOLpro) were assessed. Tertiary structure modeling (GalaxyWEB) and refinement (GalaxyRefine) were performed. Docking (PatchDock) and dynamics simulations (GROMACS, 100 ns) evaluated TLR2-vaccine binding stability. Immune response was simulated (C-ImmSim), and codon optimization (JCAT) ensured <i>E. coli</i> expression compatibility.</p><p><strong>Results: </strong>Non-allergenic, antigenic (VaxiJen score: 0.52), stable (instability index: 30.20), and soluble (GRAVY: -0.548). Molecular weight: 34 kDa; pI: 9.65. RMSD (3.8 nm) and RMSF analyses confirmed complex stability. Free energy landscape revealed low-energy binding states (0.3-1.8 kcal/mol). Simulated results showed robust IgG/IgM production, Th1 cytokines (IFN-γ, IL-2), and memory cell activation. Epitopes covered 100% of populations in Europe/North America and > 77% in Africa/South Asia.</p><p><strong>Conclusion: </strong>The multi-epitope vaccine demonstrated strong immunogenicity, structural stability, and broad population coverage. Computational validation supports its potential as a candidate for preventing VZV infections, pending experimental verification in the future.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30994"},"PeriodicalIF":2.2,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12579738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145439827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A subspace learning aided matrix factorization for drug repurposing.","authors":"Amir Mahdi Zhalefar, Zahra Narimani","doi":"10.34172/bi.30443","DOIUrl":"10.34172/bi.30443","url":null,"abstract":"<p><p></p><p><strong>Introduction: </strong>Design and development of new drugs needs a huge amount of investment of time and money. The advent of machine learning and computational biology has led to sophisticated techniques for drug repositioning, i.e., recommending available drugs for new diseases or, more specifically, protein targets. However, there remains a critical need for improved synergy between these techniques to enhance their predictive accuracy and practical application in clinical settings.</p><p><strong>Methods: </strong>This study presents a novel approach that integrates two methodologies: SLSDR, a sparse and low-redundant subspace learning-based dual-graph regularized robust feature selection technique, and the iDrug method for drug repurposing which integrates different domains. SLSDR is a subspace learning algorithm based on matrix factorization, and iDrug is a matrix factorization-based drug repositioning method that integrates data from two different domains (drug-disease and drug-target domains). By leveraging SLSDR's ability to extract essential features from drug-disease and drug-target spaces, we enhance the iDrug objective function. Our approach includes constructing a drug-drug similarity matrix using a feature space derived from SLSDR, and target-target and disease-disease similarity matrices. This ensures a comprehensive representation of drug-disease and drug-target associations. We introduce a novel objective function that captures the nuanced interactions between drugs and diseases, considering the complex interrelationships among features within all the datasets.</p><p><strong>Results: </strong>By integrating these components, our strategy offers a holistic solution for drug repositioning, optimizing the prediction process. In terms of prediction accuracy, AUC, AUPR and computing efficiency, the results indicate notable gains over the state of the art drug repurposing methods. Fig. 1, represents the comparison of the performance of the proposed method with existing approaches across various metrics.</p><p><strong>Conclusion: </strong>The proposed matrix factorization based method for drug repurposing, benefits from integrating knowledge from two domains, drug-disease and drug-target domains, and also is capable of preserve the geometry of the data in both feature space, and s ample space. Comparing to existing state of the art methods, this shows accuracy improvement in drug repurposing.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30443"},"PeriodicalIF":2.2,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12705283/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145775296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"microRNAs shuttled by mesenchymal stromal cell-derived exosomes in coronary artery disease: A systematic review of preclinical studies.","authors":"Soroush Mostafavi, Amin Arasteh, Seyedeh Mina Mostafavi Montazeri, Seyyedeh Mina Hejazian, Farahnoosh Farnood, Sima Abediazar, Abolfazl Barzegari, Sepideh Zununi Vahed","doi":"10.34172/bi.30989","DOIUrl":"10.34172/bi.30989","url":null,"abstract":"<p><strong>Introduction: </strong>Coronary artery disease (CAD) is a life-threatening cardiac condition with high morbidity and mortality worldwide. This systematic review article highlighted the therapeutic roles of mesenchymal stromal cells (MSCs)-derived exosomal microRNAs (exo-miRs) in preclinical models of CAD.</p><p><strong>Methods: </strong>A comprehensive search was conducted on PubMed, Web of Science, Scopus, and Google Scholar to identify relevant publications until 04 Apr 2025. The literature review focuses on the origin of MSCs, the technique employed for exosome extraction and identification, the route and frequency of exosomal administration, the mechanisms through which exo-miRs regulate paracrine activity, and their impact on cardiac outcome.</p><p><strong>Results: </strong>After meticulous evaluation, fifty-six studies were deemed eligible for inclusion in this systematic review. Bone marrow-derived MSCs were the most commonly utilized cell type in the preclinical studies. The majority of studies employed the ultracentrifugation method for exosome isolation from MSCs. The administration of exosomes was primarily achieved through a single intramyocardial injection, utilizing a wide range of exosome concentrations (ranging from 0.02-400 μg/μL).</p><p><strong>Conclusion: </strong>The included studies predominantly have reported the anti-inflammatory, anti-apoptotic, angiogenic, antifibrotic, and reparative effects of MSC-exo-miRs, especially under hypoxic conditions. These findings support the capacity of MSC-exo-miRs to regulate the immune system and facilitate cardiac recovery following an injury.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30989"},"PeriodicalIF":2.2,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolutionizing cancer therapy: Monoclonal antibodies in radiosensitization.","authors":"Abolfazl Bemidinezhad, Yasaman Abolhassani, Mojgan Noroozi-Karimabad, Arman Abroumand Gholami, Abbas Alalikhan, Ramin Roshani, Mohammad Parsa-Kondelaji, Fatemeh Gheybi","doi":"10.34172/bi.30996","DOIUrl":"10.34172/bi.30996","url":null,"abstract":"<p><p>Cancer treatment has advanced significantly, yet traditional modalities such as radiotherapy still encounter challenges, including damage to healthy tissues and limited tumor specificity. Monoclonal antibodies (mAbs) have emerged as powerful tools in oncology, offering particular therapeutic options with reduced toxicity. Their capacity to enhance the efficacy of radiotherapy through radiosensitization presents a promising strategy for improving cancer outcomes. This review synthesizes findings from the past decade, providing an in-depth analysis of the diverse roles of mAbs in radiosensitization. Key mechanisms are discussed, including targeting molecular pathways, modulation of immune responses, and integration with novel platforms such as nanoparticles and antibody-drug conjugates (ADCs). The review also highlights the successes of preclinical and clinical studies while addressing ongoing challenges like delivery inefficiencies, tumor resistance, and antigen heterogeneity. Additionally, emerging alternatives including aptamers, nanobodies, and engineered proteins are explored as potential solutions to these barriers. Advancements in mAb-based delivery systems and combination therapies remain crucial for achieving more personalized and effective cancer treatments.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30996"},"PeriodicalIF":2.2,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent innovations in nanomedicine and nano-based techniques for the treatment of breast cancer.","authors":"Meena Bhandari, Seema Raj, Md Sabir Alam","doi":"10.34172/bi.30804","DOIUrl":"10.34172/bi.30804","url":null,"abstract":"<p><p>Breast cancer (BC) is a persistent global health challenge, necessitating innovative therapeutic strategies. Recently, nanotechnology has appeared as a transformative methodology to treat BC, suggesting precise targeting, controlled drug delivery, and improved imaging capabilities. This review offers a current overview of the latest innovations around nanotechnology for BC therapy in the field of new nanomedicines and nano-based drug delivery methods by carefully examining the utilization of nanoparticles to enhance the effectiveness of both new and old medications and to enable targeted evaluation using disease markers. Key topics include early detection, targeted drug delivery, multimodal imaging, and combination therapies. The paper underscores the probability of using nanotechnology to reshape BC management landscape and outlines potential future directions.</p>","PeriodicalId":48614,"journal":{"name":"Bioimpacts","volume":"15 ","pages":"30804"},"PeriodicalIF":2.2,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}